Hologic, Inc. (NASDAQ:HOLX) Director Lawrence M. Levy sold 2,960 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $44.54, for a total value of $131,838.40. Following the transaction, the director now directly owns 45,634 shares of the company’s stock, valued at approximately $2,032,538.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Hologic, Inc. (HOLX) traded up 1.58% during trading on Monday, reaching $45.02. The company had a trading volume of 1,608,226 shares. Hologic, Inc. has a 52 week low of $32.81 and a 52 week high of $46.05. The stock has a 50 day moving average price of $44.25 and a 200 day moving average price of $41.75. The firm has a market capitalization of $12.61 billion, a P/E ratio of 16.14 and a beta of 0.94.
Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.46 by $0.04. Hologic had a net margin of 27.31% and a return on equity of 25.26%. The firm had revenue of $715.40 million during the quarter, compared to the consensus estimate of $685.24 million. During the same quarter last year, the firm earned $0.47 EPS. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. Analysts predict that Hologic, Inc. will post $2.01 earnings per share for the current year.
WARNING: This article was first published by BBNS and is the property of of BBNS. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://baseballnewssource.com/markets/hologic-inc-holx-director-lawrence-m-levy-sells-2960-shares-updated/985174.html.
A number of hedge funds have recently bought and sold shares of HOLX. Martingale Asset Management L P increased its stake in Hologic by 23.3% in the fourth quarter. Martingale Asset Management L P now owns 406,802 shares of the medical equipment provider’s stock valued at $16,321,000 after buying an additional 76,831 shares during the period. Tyers Asset Management LLC bought a new stake in Hologic during the fourth quarter valued at $454,000. FIL Ltd bought a new stake in Hologic during the fourth quarter valued at $4,541,000. Cigna Investments Inc. New bought a new stake in Hologic during the fourth quarter valued at $1,757,000. Finally, STA Wealth Management LLC bought a new stake in Hologic during the fourth quarter valued at $305,000. Hedge funds and other institutional investors own 94.47% of the company’s stock.
A number of research analysts recently weighed in on the company. Jefferies Group LLC set a $49.00 price objective on Hologic and gave the company a “buy” rating in a research report on Sunday, May 28th. Zacks Investment Research lowered Hologic from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. BTIG Research reaffirmed a “buy” rating and set a $47.00 price objective on shares of Hologic in a research report on Sunday, May 14th. Leerink Swann reissued an “outperform” rating and issued a $52.00 target price on shares of Hologic in a report on Thursday, March 30th. Finally, Needham & Company LLC lifted their target price on Hologic from $46.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, April 4th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $47.54.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with our FREE daily email newsletter.